Baidu
map

Molecular cell:关键突变导致癌细胞代谢“重连”促进药物抵抗

2015-07-07 佚名 生物谷

                                                       &nbs

                                                        

最近,来自艾默里大学的科学家发现在许多黑色素瘤中存在一个重要基因突变能够使癌细胞的代谢重新连线,使癌细胞的生长依赖于一种参与酮体生成的催化酶,这一发现为解决黑色素瘤细胞对靶向药物的抵抗,开发新的替代药物提供了深入见解,同时也部分解释了为什么这一突变在黑色素瘤细胞中频发。近日,相关研究结果发表在国际学术期刊molecular cell。
 
B-raf基因发生V600E突变在黑色素瘤细胞中非常常见,这一突变能够促进癌细胞生长,除了在黑色素瘤中存在,在一些结肠癌和甲状腺癌病例中也发现存在B-raf V600E突变。目前已经开发出一些针对B-raf V600E基因突变的靶向药物,但在临床实验中发现,在癌症得到明显改善之后,携带V600E基因突变的癌细胞都不可避免地产生药物抗性。
 
在这项研究中,研究人员发现B-raf V600E基因突变能够刺激癌细胞产生更多的HMG-CoA裂解酶,携带V600E突变的黑色素瘤细胞生长非常依赖于该酶,而其他的黑色素瘤细胞则不会。HMG-CoA裂解酶是酮体生成途径中一个重要酶,能够帮助机体在血糖水平较低时降解脂肪酸以获得能量。酮体生成途径能够受到低糖,高脂饮食刺激激活,通常发生于肝脏,但B-raf V600E基因突变启动了癌细胞中的酮体生成,以维持癌细胞生长存活。除此之外,研究人员还发现酮体生成途径的重要产物乙酰乙酸能够刺激携带B-raf V600E基因突变的癌细胞继续增殖。
 
总得来说,这项研究证明B-raf V600E基因突变能够使黑色素瘤细胞中的代谢途径重新连线,增强癌细胞对酮体生成途径的依赖性,这一发现对于解决黑色素瘤细胞对靶向药物的抵抗,开发新的替代药物具有重要意义。

原始出处:

Hee-Bum Kang14, Jun Fan14, Ruiting Lin14, Shannon Elf, Quanjiang Ji, Liang Zhao, Lingtao Jin, Jae Ho Seo, Changliang Shan, Jack L. Arbiser, Cynthia Cohen, Daniel Brat, Henry M. Miziorko, Eunhee Kim, Omar Abdel-Wahab, Taha Merghoub, Stefan Fröhling, Claudia Scholl, Pablo Tamayo, David A. Barbie, Lu Zhou, Brian P. Pollack, Kevin Fisher, Ragini R. Kudchadkar, David H. Lawson, Gabriel Sica, Michael Rossi, Sagar Lonial, Hanna J. Khoury, Fadlo R. Khuri, Benjamin H. Lee, Titus J. Boggon, Chuan He, Sumin Kangcorrespondenceemail, Jing Chen.Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.Molecular Cell.July 2, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-11-15 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 jambiya
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869152, encodeId=b57d186915246, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 10:57:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959406, encodeId=ad70195940618, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 15 21:57:00 CST 2015, time=2015-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252037, encodeId=d786125203e18, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370827, encodeId=048013e0827bc, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529446, encodeId=c9e115294464c, content=<a href='/topic/show?id=ba3be7774b6' target=_blank style='color:#2F92EE;'>#细胞代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77774, encryptionId=ba3be7774b6, topicName=细胞代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=771d11946860, createdName=yangshch, createdTime=Wed Jul 08 23:57:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31607, encodeId=e3b43160e79, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:21:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 huaxipanxing

    看看

    0

相关资讯

NEJM:Nivolumab和易普利姆玛联合或单药治疗未经治疗过的黑色素瘤

    背景  Nivolumab(一个程序性死亡1[PD-1]检查点抑制剂)和易普利姆玛(一种细胞毒性T淋巴细胞相关抗原4[CTLA-4]检查点抑制剂)已被证明在转移性黑色素瘤中具有互补活性。这项随机,双盲,3期研究对nivolumab单独或nivolumab加易普利姆玛与易普利姆玛单独治疗转移性黑色素瘤患者进行了比较。    方法  

PD-1免疫疗法监管重大里程碑:百时美Opdivo获欧盟批准,系欧洲PD-1疗法

PD-1/PD-L1免疫治疗领域近日在监管方面迎来重大里程碑!由百时美施贵宝(BMS)研发的PD-1免疫疗法Opdivo(nivolumab)喜获欧盟批准治疗晚期黑色素瘤,使其成为首个撬开欧洲市场的PD-1免疫疗法,同时也是首个成功拿下日本、美国、欧盟3大主要市场的PD-1免疫疗法。而同时令人期待的是,Opdivo肺癌申请极有可能在7月份获批,成为欧洲市场首个治疗非小细胞肺癌的PD-1免疫疗法。

NEJM:Nivolumab和易普利姆玛联合治疗或单药治疗黑色素瘤

背景:Nivolumab(一个程序性死亡1[PD-1]检查点抑制剂)和易普利姆玛(细胞毒性T淋巴细胞相关抗原4 [CTLA-4]检查点抑制剂)在转移性黑色素瘤中已显示出互补活性。在这项随机,双盲,3期研究中,nivolumab单独治疗或nivolumab合并易普利姆玛治疗与易普利姆玛单独治疗转移性黑色素瘤患者中进行比较。    方法:研究人员以1:1:1的比例,将94

JAMA:PDE5抑制剂可能增加了恶性黑色素瘤的风险

    背景  对于口服勃起功能障碍药物的靶点,5型磷酸二酯酶(PDE5)抑制剂,是与恶性黑色素瘤的发展途径密切相关的一部分。最近报道西地那非使用者的恶性黑色素瘤的风险增加。    意义  为了检测使用PDE5抑制剂和黑素瘤风险之间的联系,包括特定PDE5抑制剂的数据,处方编号,和黑素瘤的阶段。    方法  

肿瘤免疫疗法——多突变癌症克星

肿瘤中的基因突变越多,新免疫疗法就越有效。人类结肠癌细胞。图片来源:URBAIN WEYEMI, CHRISTOPHE E. REDON, WILLIAM M. BONNER 临床试验中使用的新型免疫系统激活抗癌药物让许多看似无法治愈的黑素瘤或肺癌患者重获新生,但这些药物对结肠癌似乎无效。不过有一个例外——一位男性患者的结肠癌转移瘤在2007年接受药物治疗后消失了——引起了研究人员的兴趣

ASCO 2015:黑色素瘤,口腔癌,脑转移癌以及儿童癌症的新近进展

2015年5月31日,芝加哥——第51届美国临床肿瘤学会(ASCO)会上提供了:关于儿童癌症生存期不积极治疗的影响;口腔癌手术的最佳时机;脑转移癌患者整个大脑辐射使用的长期的、结论性答案。另一项研究提供了针对黑色素瘤患者强有效的新免疫治疗选择。所有四项研究在ASCO的全体会议上发布,这些特征研究最可能影响患者的治疗。在美国,这些有望立即影响肿瘤治疗的临床实践的进展,将带来患者生存期和生活质量的改善

Baidu
map
Baidu
map
Baidu
map